|
|
Profile
|
Delegates :
Taku Nakahara |
|
Incorporated :
January 17 , 2020 |
Paid in Capital :
90 Million yen |
Employees :
17 人 |
Address :
Muzukami 246-2, Kakuganji, Tsuruoka-city YAMAGATA
〒997-0052
|
TEL/FAX :
/ |
URL：
https://www.metagentx.com/en/ |
Attachment :
 【会社概要資料】メタジェンセラピューティクス株式会社.pdf [ 2.1MiB ] |
Mission/Background :
Metagen Therapeutics, Inc. is a biotech startup founded in 2020、by a physician from Japan’s renowned teaching hospital and researchers from Japan’s top universities. The company’s mission is “Living up to the hopes of patients through microbiome science”, with the aim to create social impact through medical care and drug discovery based on gut microbiome research. The company is also promoting the social implementation of Fecal Microbiota Transplantation (FMT), a treatment method in which the microbiota contained in the stool of a healthy person is transplanted into the intestine of a patient to rebuild the patient’s gut environment, as well as conducting proprietary microbiome drug discovery. Through establishing an Intestinal Microbiota Bank, the company aims to realize a "gut health sharing society" in which gut bacteria from healthy people can be delivered to patients who need them. |
|
Technology & Business
|
FMT: A procedure where microbiota in the stool of a healthy donor is transplanted to the intestines of a patient via colonoscopy. As a medical technology that attempts to treat diseases caused by intestinal imbalance disorders, or dysbiosis, it is essential to have a microbiota bank for stool sourcing, and we are developing this bank in collaboration with Juntendo University.
Microbiome Drug Discovery: We target the gut bacteria as well as the mechanisms of action derived from basic research into microbiota, and are working on FMT-based drug discovery through Reverse Translational Research, which focuses on the practical application of drugs to proceed its development with a higher probability of safety and efficacy than usual. We aim to commercialize drugs by confirming in advance through clinical research using FMT and narrowing down the active ingredients (from different types of gut microbiota), which increases the overall success rate of drug development.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
MGT-001
|
Phase3
|
FMT for ulcerative colitis (Medical Technology) ※Implemented as Advanced Medical Care B Program from January 2023.
|
Aiming to complete clinical trials and obtain subsequent reimbursement under Advanced Medical Care B Program.
|
MGT-007
|
Phase1/2
|
Intestinal FMT for gastrointestinal cancer (combination therapy w/immune checkpoint inhibitors). Specific clinical research.
|
Safety and efficacy confirmation of combination therapy with immune checkpoint inhibitors.
|
MGT-006
|
Preclinical
|
Drugs for ulcerative colitis
|
Investigational drug manufacturing facility construction drug manufacturing together with clinical trials in Japan and overseas.
|
|
|
|
|
|
|
|
|
|
Highlights
|
2024/8:Together with National Cancer Center Hospital and Juntendo University, initiated Japan's first clinical trial to investigate safety and efficacy of FMT therapy for gastrointestinal cancer.
2024/6:Ulcerative Colitis drug development project selected for national grant.
2024/4:Launched Japan's first intestinal microbiota bank to recruit stool donors.
2023/1:Antibiotic FMT for ulcerative colitis approved for national fast track program with governmental assessments toward Health Insurance coverage.
|
|
Hot news
|
In August 2024, we announced our plans to open Japan's first stool donation facility, " Tsuruoka Gut Microbiota Donation Site," in the Tsuruoka Science Park in Tsuruoka City, Yamagata Prefecture. The facility is scheduled to open April 2025 and will focus on recruiting potential donors in the Shonai area centering on Tsuruoka City and collaborating with nearby medical institutions.
|
|
Alliance strategy
|
Seeking licensee for MGT-006 (Non-clinical stage, selected for national grant), an oral FMT drug in the pipeline for treating ulcerative colitis. Based on data from previous clinical studies, probability of success in obtaining a POC is extremely high.
Planning to obtain data correlating with therapeutic efficacy and safety in clinical trial of FMT with gastrointestinal cancer, which began August 2024, and are also seeking partners for drug discovery research or expansion to other types of cancer.
|
|
|